ȯ 94% ü , ȯڴ ü ʾֱ ϸ ȯڰ 2 3~4ְ ڷγ19 ϴ mRNA ſ 鿪 Ÿ´ٰ Ѵ.
ȯڵ Ϲε ڷγ19 ̳ պ̳ δ Ȱ , ȯڵ鿡 ȿ ʹ .
ڷγ19 mRNA ſ 鿪 ϱ 131 ȯڸ غҴ. 94% ڷγ̷ ü 7 ȯڴ ü ʾҴ.
mRNA ſ ȯ ڷγ19 ̷ ̵ ȣϴ ٷҴ ߴ. ػ罺 б コ Ͽ ڵ ش Ϳ ڸ ִ ̽ ڻ ̷ ߴ.
츮 ̵ ȯڿԼ ̷ ϴ ü ߰ . ̰ ġ ִ. ȯڵ鿡Դ ġᰡ Ŀ 3 ؾ߸ ϴ°?
翡 Ե ȯڵ 63 κ 106 ־ 25 ־. ̹ ų ̳ ȣŲ ִ ȯڵ ִ ȯڵ麸 ɼ ٰ ߴ.
ȯ, Ŀ ؾϰ ڰ鿪 ȯ ġϴµ ϴ Ŭ ü ø ȯڵ鿡Լ 6 ȿ ü ʾҴ. ȭп ġḦ ȯڵ ü Ϲε鿡 ߴ. ̰ ڷγ19 Ǵ 츮 Ѵٰ ڻ ߴ.
ִ ȯڵ Ŀ ؼ ؾ߸ ϴ ûѴ. ķ Ÿ ü ٸ ü ʾҴ. ȯڵ ο T B м ʾҴ.
80% (ƾ Ƹī) , 18% ƾ Ƹī , 2% ̴ ǥ ũⰡ ũٸ 鿪 ִ ǹѴ.
츮 鿪 ̰ ִ ˾ƺ ̷ ΰ ƽþΰ ƾ Ƹī ȯڵ鿡 ؼ ǽ Ѵٰ ̽ ̻ 纥 ڻ簡 ߴ.
:
A. Addeo et al., 'Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer' Cancer Cell. 2021 Jun 18;S1535-6108(21)00330-5. doi: 10.1016/j.ccell.2021.06.009.